EORTC CLTF 2018 Meeting Cutaneous Lymphoma:

biology, treatment, and patient view



The digital/flip book edition of all accepted abstracts is available here: EJC Vol. 101 Supplement


Please find below the overview of the oral abstract presentations.


Session 1 / Biologic Insights I - Molecular markers and targets


001 Adele De Masson Tumor clone frequency is a robust predictor of progression and survival in patients with Stage IB mycosis fungoides
020 Maxime Battistella KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia (ATLL)
021 Jin Ah Yoo Identification of predictive markers for stage progression in primary cutaneous anaplastic large cell lymphoma
022 Safa Najidh Standardized flow cytometry (EuroFlow) demonstrates heterogeneous T-cell origin of Sézary lymphoma cells
027 Lise M. Lindahl Prognostic miRNA classifier in early-stage mycosis fungoides: Development and validation in a Danish nationwide study
032 Duncan Murray The tumour phenotype of mycosis fungoides clusters into three heterogeneous surface expression profiles
042 Ulrike Wehkamp Dysregulation of the expression of antimicrobial peptides in patients with cutaneous T-cell lymphoma
008 Anne Hald Rittig Differences in the miRNA expression profiles of erythrodermic mycosis fungoides and Sézary syndrome
028 Helene Moins-Teisserenc Revisiting blood classification in Mycosis Fungoides and Sézary syndrome with the KIR3DL2 marker


Session 2 / PROCLIPI analysis


015 Julia Scarisbrick The PROCLIPI Study; A prototype registry for rare disease with global collaboration for establishment of a prognostic index in mycosis fungoides and Sezary syndrome
092 Pietro Quaglino Treatment of early-stage Mycosis fungoides: results from the PROCLIPI Study
044 Alejandro Gru Updates from the Central Pathology Review in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS) for the Global PROCLIPI Study
070 Emmilia Hodak Lymph Node Imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease


Session 3 / Biologic Insights II - Genomics and molecular biology


003 Matthias Borgmann  Resminostat affects transcriptional regulation of disease-related processes in CTCL
010 Lilach Moyal The bioactive content of CTCL cell line-derived exosomes and small microvesicles: First study in CTCL
019 Armando Bastidas Torres Genomic analysis reveals recurrent deletion of HNRNPK and SOCS1 in mycosis fungoides
029 Bence Bátai 1p36 deletion is associated with TNFRSF14 mutations in primary cutaneous follicle center lymphoma
033 Rosie Butler Functional interrogation of STAT5 variants in Primary Cutaneous T-cell Lymphoma (CTCL)
036 Raquel Rabionet Methylation analysis in Sézary syndrome and integration of exome and transcriptome data
038 Charlotte Flanagan Mutations in highly conserved phosphatase PP5 identified in CTCL lead to dysregulation of the MAPK pathway
041 Jonathan Davick Genomic alterations using OncoScan in adult T-cell leukemia/lymphoma: a characterization of 69 cases from Peru, the United States, Brazil, and Spain


Session 4 / Quality of Life


107 Constanze Jonak Health-related quality of life in cutaneous lymphomas: a state-of-the-art review
104 John Zic Audience Poll
103 Chenjing Peng The impact of skin infection on quality of life in patients with mycosis fungoides and Sezary syndrome
106 Kevin Molloy Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sézary syndrome and those with more extensive skin involvement
105 Pierluigi Porcu Quality of life in cutaneous T cell lymphoma patients treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from MAVORIC
104 John Zic Managing HRQL in patients with CTCL: physician responses from the 2018 USCLC Workshop
  Susan Thornton The Lymphoma Coalition global patient Survey


Session 5 / Biologic Insights III - Transational research


035 Lluis Espinosa Establishment of an in vivo model of patient-derived SS for therapy validation
037 Tanja Schläpfer  The assessment of immune-regulatory effects of extracorporeal photopheresis in leukemic cutaneous T cell lymphoma, graft-versus-host disease and lung transplant rejection
040 Larisa Geskin An integrated data resource for genomic analysis of cutaneous T-cell lymphoma


Session 6 / Histopathology

002 Denis Miyashiro Understanding the tumor microenvironment in the primary cutaneous CD30-positive lymphoproliferative disorders
004 Alessandro Pileri The role of immune-checkpoints in mycosis fungoides
15 min Werner Kempf Dermal CD8+ lymphoproliferations - results of the EORTC CLTF task force histopathology group workshop Zurich 2017
024 Christiane Querfeld The regulation of PD-L1 expression by miRNAs in cutaneous T-cell lymphoma
061 Silvia Alberti-Violetti Indolent cytotoxic cutaneous lymphomas with clinical and histological features of atypical lymphoid proliferation not otherwise specified.
043 Alejandro Gru Clinicopathologic characteristics, prognostic and predictive biomarkers in Adult T-cell leukemia / Lymphoma (ATLL): A Characterization of 79 Cases from the Western Hemisphere


Session 7 / Treatment and clinical aspects


085 Taqdees Suhail A novel approach to low dose Total skin electron beam therapy (TSEBT)
108 Keiji Iwatsuki Hydroa vacciniforme and hydroa vacciniforme-like lymphoproliferative disorder: Disease spectrum, responsible T-cell subsets and prognosis
094 Vieri Grandi 18F-FDG-PET/CT for staging Mycosis Fungoides and Sezary Syndrome.
069 Jade Cury Martins Granulomatous slack skin: a series of cases
093 Christiane Querfeld Intralesional Injection of the CD47-blocking Immune Checkpoint Inhibitor TTI-621 (SIRPaFc) Induces Antitumor Activity Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase 1 Trial
086 Oleg Akilov Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoides


Session 8 / Treatment and clinical cases


077 Rudolf Stadler Resminostat for Maintenance Treatment of Patients with Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) – a Status Update
050 Marie-Charlotte Brüggen Aggressive rare T cell lymphomas with manifestation in the skin: a monocentric cross-sectional case study
013 Stefan Schieke Single-cell variability drives phenotypic heterogeneity and intrinsic drug-resistance in cutaneous T-cell lymphoma
078 Martine Bagot IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
079 Jan Nicolay Overcoming cell death resistance in cutaneous T cell lymphoma (CTCL) by combined Bcl-2 and NF?B inhibition
081 Iris Amitay-Laish Does treatment with anti-tumor necrosis factor alpha have an effect on primary cutaneous lymphoma?
090 Rose Moritz Adverse bystander effect of localized electron beam irradiation - a negative abscopal effect?


Session 9 / Treatment and clinical cases


016 Rutger Melchers Frequency of associated haematologic malignancies in lymphomatoid papulosis: a preliminary report of 505 patients from the Dutch Cutaneous Lymphoma Group
088 Olivier Gaide Sezary syndrome, 3 injections of alemtuzumab may suffice
058 Pietro Quaglino Sezary Syndrome: A single center retrospective study with proposal for a clinical score system
097 Francesco Onida Allogeneic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: 2018 update of the Milan experience
099 Lidia Maroñas-Jiménez Translational research with topical calcineurin inhibitors in early MF
100 Michael Khodadoust Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
101 Auris Huen Updated Combined Analysis of Two Phase II Studies of Brentuximab Vedotin in Patients with Mycosis Fungoides and Sézary Syndrome


Session 10 / Treatment and clinical cases


034 Vassiliki Bakou Cytokine profile alterations in Cutaneous T-cell Lymphoma cell lines after Lenalidomide and/or Bortezomib treatment
091 Emmilia Hodak Pediatric mycosis fungoides: management and outcomes with special focus on the folliculotropic variant
098 Stephen Morris Reduced Intensity allogeneic stem cell transplantation for advanced stage Mycosis Fungoides and Sezary Syndrome series of 53 patients from the UK.


Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05